Investigational drug · Phase 2
KQB198
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "KQB198"
First trial start
2026
Jun 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KQB198", any sponsor or status.
Conditions studied
As listed on its trial records.
- GIST - Gastrointestinal Stromal Tumor
- GIST
- GIST Metastatic Cancer
- Gastro Intestinal Stromal Tumour
- Gastrointestinal Tumors
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "KQB198" as an intervention, largest first.
Kumquat Biosciences Inc.Industry
NCT06720987 · 140 participants (planned) · Start Feb 4, 2025 · Primary completion Jun 30, 2029
Drug: KQB365; Cetuximab and 1 more · For: KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies and 6 more
Sites: Phoenix, Arizona; Denver, Colorado; Jacksonville, Florida · 11 sites in all
- A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesActive, not recruiting
Kumquat Biosciences Inc.Industry
NCT06507306 · 92 participants · Start Jun 3, 2024 · Primary completion Dec 31, 2026
Drug: KQB198; Osimertinib and 1 more · For: Solid Tumor, Adult
Sites: Denver, Colorado; Orlando, Florida; Sarasota, Florida · 26 sites in all
Kumquat Biosciences Inc.Industry
NCT07406633 · 46 participants (planned) · Start Jun 23, 2026 · Primary completion Oct 2027
Drug: KQB198; Imatinib (Gleevec) · For: GIST - Gastrointestinal Stromal Tumor; GIST; GIST Metastatic Cancer and 2 more
Sites: Los Angeles, California; Jacksonville, Florida; Miami, Florida · 17 sites in all
- A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic MalignanciesActive, not recruiting
Kumquat Biosciences Inc.Industry
NCT06645886 · 13 participants · Start Dec 9, 2024 · Primary completion Mar 2027
Drug: KQB198; Dasatinib · For: Hematologic Malignancies; Adult
Sites: San Francisco, California; Denver, Colorado; Tampa, Florida · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for GIST - Gastrointestinal Stromal Tumor
- NB003Phase 31 trial
Ningbo Newbay Technology Development Co., Ltd · GIST - Gastrointestinal Stromal Tumor, Advanced
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.